Total Payments
$216,162
2024 Payments
$18,319
Companies
46
Transactions
1,087
Medicare Patients
4,179
Medicare Billing
$395,203
Payment Breakdown by Category
Other$162,743 (75.3%)
Consulting$22,027 (10.2%)
Food & Beverage$21,034 (9.7%)
Travel$8,476 (3.9%)
Research$1,668 (0.8%)
Education$214.24 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $162,743 | 82 | 75.3% |
| Consulting Fee | $22,027 | 10 | 10.2% |
| Food and Beverage | $21,034 | 907 | 9.7% |
| Travel and Lodging | $8,476 | 67 | 3.9% |
| Unspecified | $1,668 | 15 | 0.8% |
| Education | $214.24 | 6 | 0.1% |
Payments by Type
General
$214,495
1,072 transactions
Research
$1,668
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $57,031 | 244 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $49,052 | 205 | $0 (2024) |
| GENZYME CORPORATION | $36,000 | 87 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $18,958 | 69 | $0 (2019) |
| PFIZER INC. | $17,715 | 36 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $14,604 | 43 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,033 | 80 | $0 (2024) |
| Mylan Specialty L.P. | $5,973 | 31 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,969 | 62 | $0 (2024) |
| Grifols USA, LLC | $627.14 | 33 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,319 | 122 | GENZYME CORPORATION ($9,656) |
| 2023 | $40,378 | 160 | GlaxoSmithKline, LLC. ($21,553) |
| 2022 | $27,573 | 138 | GENZYME CORPORATION ($11,469) |
| 2021 | $14,883 | 75 | GENZYME CORPORATION ($6,382) |
| 2020 | $13,005 | 53 | GlaxoSmithKline, LLC. ($8,179) |
| 2019 | $40,899 | 192 | GlaxoSmithKline, LLC. ($17,133) |
| 2018 | $36,581 | 192 | AstraZeneca Pharmaceuticals LP ($13,534) |
| 2017 | $24,525 | 155 | AstraZeneca Pharmaceuticals LP ($11,091) |
All Payment Transactions
1,087 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: Pulmonology | ||||||
| 12/20/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $21.58 | General |
| Category: HFCWO | ||||||
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $7.03 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Inflammation | ||||||
| 11/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | Baxter Healthcare | Hillrom - Monarch Airway Clearance System (Device) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Airway Clearance Device | ||||||
| 11/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $0.62 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $20.92 | General |
| Category: Medical Device | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Inflammation | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,153.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/22/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $10.91 | General |
| Category: RESPIRATORY | ||||||
| 10/22/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $6.90 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiov | GlaxoSmithKline, LLC. | $764.07 | 6 |
| A COMPARISON OF THE CLINICAL EFFECTIVENESS OF INHALED TRIPLE THERAPY ( | GlaxoSmithKline, LLC. | $375.96 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 915 | 1,197 | $338,188 | $87,738 |
| 2022 | 20 | 1,150 | 1,526 | $400,285 | $99,663 |
| 2021 | 21 | 1,208 | 1,633 | $273,819 | $112,240 |
| 2020 | 20 | 906 | 1,241 | $214,106 | $95,563 |
Total Patients
4,179
Total Services
5,597
Medicare Billing
$395,203
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 76 | 145 | $61,625 | $14,255 | 23.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 29 | 69 | $107,525 | $12,128 | 11.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 128 | 181 | $36,200 | $12,057 | 33.3% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 36 | 36 | $10,800 | $10,174 | 94.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 84 | $21,000 | $8,452 | 40.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 141 | 215 | $13,975 | $4,547 | 32.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 35 | 35 | $19,998 | $3,764 | 18.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $14,950 | $3,295 | 22.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 50 | $17,500 | $3,269 | 18.7% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 60 | 64 | $4,800 | $3,168 | 66.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $6,670 | $2,943 | 44.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 61 | 63 | $7,560 | $2,807 | 37.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 28 | 28 | $2,100 | $1,292 | 61.5% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 36 | 36 | $1,440 | $1,170 | 81.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 16 | 16 | $1,200 | $1,147 | 95.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 28 | 28 | $3,052 | $905.57 | 29.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 13 | 14 | $2,800 | $775.21 | 27.7% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 22 | 22 | $3,300 | $623.26 | 18.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 19 | 19 | $760.00 | $585.00 | 77.0% |
| 94762 | Test to measure oxygen level in blood using ear or finger device continuously overnight | Office | 2023 | 16 | 19 | $798.00 | $378.25 | 47.4% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2023 | 27 | 27 | $135.00 | $0.67 | 0.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 45 | 86 | $134,016 | $15,565 | 11.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 148 | 225 | $45,000 | $15,483 | 34.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 83 | 149 | $63,325 | $12,696 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 84 | 108 | $27,000 | $10,989 | 40.7% |
About Dr. David Hill, MD
Dr. David Hill, MD is a Pulmonary Disease healthcare provider based in Waterbury, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033226584.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Hill, MD has received a total of $216,162 in payments from pharmaceutical and medical device companies, with $18,319 received in 2024. These payments were reported across 1,087 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($162,743).
As a Medicare-enrolled provider, Hill has provided services to 4,179 Medicare beneficiaries, totaling 5,597 services with total Medicare billing of $395,203. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Waterbury, CT
- Active Since 08/23/2006
- Last Updated 09/13/2011
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1033226584
Products in Payments
- DUPIXENT (Biological) $49,247
- TRELEGY ELLIPTA (Drug) $31,283
- LONHALA MAGNAIR (Drug) $18,787
- CHANTIX (Drug) $16,301
- BEVESPI AEROSPHERE (Drug) $15,216
- BREZTRI (Drug) $13,178
- FASENRA (Drug) $8,718
- SYMBICORT (Drug) $6,860
- DALIRESP (Drug) $4,240
- STIOLTO RESPIMAT (Drug) $3,827
- YUPELRI (Drug) $3,337
- OFEV (Drug) $2,700
- Yupelri (Drug) $2,597
- ANORO (Drug) $1,552
- ELIQUIS (Drug) $1,364
- NUCALA (Biological) $1,117
- XOLAIR (Biological) $797.09
- GLASSIA (Biological) $698.43
- FEVIPIPRANT (Drug) $683.00
- TEZSPIRE (Biological) $605.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.